Dr. Harald Hampel, MD, PhD, MA, MSc: Genomic Analysis of ANAVEX 2-73 in Alzheimer Disease Study
ANAVEX®2-73 demonstrated continued favorable safety and tolerability through 148 weeks.
“These results further confirm the impact of actionable genetic variants that were previously identified through a full, unbiased genomic analysis of ANAVEX®2-73 in Alzheimer’s disease, raising optimism for the future of biomarker-guided precision medicine to effectively combat this devastating disease,” said Professor Harald Hampel, M.D., Ph.D., M.A., M.Sc., AXA Research Fund & Sorbonne University Excellence Chair, Departments of Neuroscience and Neurology, Sorbonne University, Paris, France. Professor Hampel is the president of the Alzheimer Precision Medicine Initiative (APMI).
Market Data 
Markets 
